山东大学学报 (医学版) ›› 2021, Vol. 59 ›› Issue (4): 70-78.doi: 10.6040/j.issn.1671-7554.0.2021.0166
孔雪1,2,李娟1,2,段伟丽1,2,史爽1,2,李培龙1,2,杜鲁涛1,2,毛海婷1,王传新1,2
KONG Xue1,2, LI Juan1,2, DUAN Weili1,2, SHI Shuang1,2, LI Peilong1,2, DU Lutao1,2, MAO Haiting1, WANG Chuanxin1,2
摘要: 目的 探讨长链非编码RNA(lncRNA)AC012073.1在乳腺癌中的表达及对细胞迁移侵袭的影响,并对其临床价值进行研究。 方法 运用高通量芯片和TCGA数据挖掘分析在乳腺癌组织中高表达并与患者预后不良相关的lncRNAs。实时荧光定量PCR(qRT-PCR)检测AC012073.1在乳腺癌细胞和血清中的表达水平。通过小干扰或质粒转染技术敲减或过表达AC012073.1,并采用Transwell和划痕实验检测其对细胞迁移与侵袭能力的影响。TargetScan等数据库对下游作用靶点和功能富集分析进行预测,并运用Cytoscape软件绘制ceRNA调控网络。采用受试者工作曲线(ROC)分析血清AC012073.1对乳腺癌的诊断效能。 结果 筛选发现一种新型lncRNA AC012073.1,并在乳腺癌组织中高表达(P<0.001),且与患者预后不良关联(P=0.031),乳腺癌细胞系中AC012073.1表达水平均高于正常乳腺上皮细胞,差异具有统计学意义(P<0.05)。MDA-MB-231和MCF-7两株细胞功能实验结果显示,敲减AC012073.1明显抑制细胞迁移和侵袭能力,反之过表达AC012073.1后,细胞的迁移和侵袭能力明显增强。下游靶点和基因通路分析结果显示,AC012073.1可通过调控肿瘤经典信号通路促进乳腺癌的进展。qRT-PCR结果显示,与健康对照相比,乳腺癌患者血清中AC012073.1的表达较高且具有统计学意义(P<0.001),ROC曲线结果显示曲线下面积(AUC)为0.833,表明其对乳腺癌具有良好的诊断价值。 结论 研究表明AC012073.1在乳腺癌中高表达,促进乳腺癌细胞的迁移和侵袭,并可能成为乳腺癌诊断和预后的生物标志物。
中图分类号:
[1] DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(6): 438-451. [2] Feng RM, Zong YN, Cao SM, et al. Current cancer situation in China: good or bad news from the 2018 global cancer statistics? [J]. Cancer Commun(Lond), 2019, 39(1): 22. doi: 10.1186/s40880-019-0368-6. [3] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28. [4] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424. [5] Rossi L, Mazzara C, Pagani O. Diagnosis and treatment of breast cancer in young women [J]. Curr Treat Options Oncol, 2019, 20(12): 86. doi: 10.1007/s11864-019-0685-7. [6] Harbeck N, Gnant M. Breast cancer [J]. Lancet, 2017, 389(10074): 1134-1150. [7] Liang Y, Zhang H, Song X, et al. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets [J]. Semin Cancer Biol, 2020, 60: 14-27. doi: 10.1016/j.semcancer.2019.08.012. [8] Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm [J]. Cancer Res, 2017, 77(15): 3965-3981. [9] Qian X, Zhao J, Yeung PY, et al. Revealing lncRNA structures and interactions by sequencing-based approaches [J]. Trends Biochem Sci, 2019, 44(1): 33-52. [10] Xu Q, Deng F, Qin Y, et al. Long non-coding RNA regulation of epithelial-mesenchymal transition in cancer metastasis [J]. Cell Death Dis, 2016, 7(6): e2254. doi: 10.1038/cddis.2016.149. [11] Xu S, Wang P, Zhang J, et al. Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer [J]. Mol Cancer, 2019, 18(1): 89. doi: 10.1186/s12943-019-1017-z. [12] Hua Q, Mi B, Xu F, et al. Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1alpha axis [J]. Theranostics, 2020, 10(11): 4762-4778. [13] Chu W, Zhang X, Qi L, et al. The EZH2-PHACTR2-AS1-ribosome axis induces genomic instability and promotes growth and metastasis in breast cancer [J]. Cancer Res, 2020, 80(13): 2737-2750. [14] Zheng S, Yang L, Zou Y, et al. Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer [J]. J Hematol Oncol, 2020, 13(1): 17. doi: 10.1186/s13045-020-00852-y. [15] Liang Y, Song X, Li Y, et al. LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis [J]. Molecular Cancer, 2020, 19(1): 85. doi: 10.1186/s12943-020-01206-5. [16] Jing H, Qu X, Liu L, et al. A novel long noncoding RNA(lncRNA), LL22NC03-N64E9.1, promotes the proliferation of lung cancer cells and is a potential prognostic molecular biomarker for lung cancer [J]. Med Sci Monit, 2018, 24: 4317-4323. doi: 10.12659/MSM.908359. [17] Li J, Hao Y, Mao W, et al. LincK contributes to breast tumorigenesis by promoting proliferation and epithelial-to-mesenchymal transition [J]. J Hematol Oncol, 2019, 12(1): 19. doi: 10.1186/s13045-019-0707-8. [18] Tang T, Guo C, Xia T, et al. LncCCAT1 promotes breast cancer stem cell function through activating WNT/beta-catenin signaling [J]. Theranostics, 2019, 9(24): 7384-7402. [19] Xiu B, Chi Y, Liu L, et al. LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription [J]. Mol Cancer, 2019, 18(1): 187. doi: 10.1186/s12943-019-1115-y. [20] Dong H, Wang W, Mo S, et al. SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88 [J]. J Exp Clin Cancer Res 2018, 37(1): 202. doi: 10.1186/s13046-018-0875-3. [21] Pan J, Fang S, Tian H, et al. lncRNA JPX/miR-33a-5p/Twist1 axis regulates tumorigenesis and metastasis of lung cancer by activating Wnt/beta-catenin signaling [J]. Mol Cancer, 2020, 19(1): 9. doi: 10.1186/s12943-020-1133-9. [22] Cheng B, Rong A, Zhou Q, et al. LncRNA LINC00662 promotes colon cancer tumor growth and metastasis by competitively binding with miR-340-5p to regulate CLDN8/IL22 co-expression and activating ERK signaling pathway [J]. J Exp Clin Cancer Res, 2020, 39(1): 5. doi: 10.1186/s13046-019-1510-7. [23] Zhuang X, Tong H, Ding Y, et al. Long noncoding RNA ABHD11-AS1 functions as a competing endogenous RNA to regulate papillary thyroid cancer progression by miR-199a-5p/SLC1A5 axis [J]. Cell Death Dis, 2019, 10(8): 620. doi: 10.1038/s41419-019-1850-4. [24] Peng W, He D, Shan B, et al. LINC81507 act as a competing endogenous RNA of miR-199b-5p to facilitate NSCLC proliferation and metastasis via regulating the CAV1/STAT3 pathway [J]. Cell Death Dis, 2019, 10(7): 533. doi: 10.1038/s41419-019-1740-9. [25] Zhan Y, Du L, Wang L, et al. Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer [J]. Mol Cancer, 2018, 17(1): 142. doi: 10.1186/s12943-018-0893-y. [26] Yuan L, Xu ZY, Ruan SM, et al. Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance [J]. Mol Cancer, 2020, 19(1): 96. doi: 10.1186/s12943-020-01219-0. [27] Jiang N, Pan J, Fang S, et al. Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer [J]. Clin Chim Acta, 2019, 495: 331-337. [28] Lin LY, Yang L, Zeng Q, et al. Tumor-originated exosomal lncUEGC1 as a circulating biomarker for early-stage gastric cancer [J]. Mol Cancer, 2018, 17(1): 84. doi: 10.1186/s12943-018-0834-9. [29] El-Ashmawy NE, Hussien FZ, El-Feky OA, et al. Serum LncRNA-ATB and FAM83H-AS1 as diagnostic/prognostic non-invasive biomarkers for breast cancer [J]. Life Sci, 2020, 259: 118193. doi: 10.1016/j.lfs.2020.118193. [30] 王琳, 董颖. 长链非编码RNA LUCAT1在结直肠癌患者血清中的表达及其意义[J]. 临床血液学杂志(输血与检验), 2020, 33(6): 851-855. WANG Lin, DONG Ying. Expression and significance of serum long non-coding RNA LUCAT1 in colorectal cancer [J]. Journal of Clinical Hematology(Blood Transfusion & Laboratory Medicine), 2020, 33(6): 851-855. |
[1] | 林芸,谢燕秋. 乳腺癌患者生育力保护及保存[J]. 山东大学学报 (医学版), 2022, 60(9): 42-46. |
[2] | 张振伟,李佳,陈克明. IGF2BP2/m6A/ITGA5信号轴调控肾透明细胞增殖和迁移[J]. 山东大学学报 (医学版), 2022, 60(9): 74-84. |
[3] | 贺士卿,李皖皖,董书晴,牟婧怡,刘宇莹,魏思雨,刘钊,张家新. 基于数据库构建乳腺癌焦亡相关基因的预后风险模型[J]. 山东大学学报 (医学版), 2022, 60(8): 34-43. |
[4] | 杨其峰,张宁. 精准医疗时代的乳腺癌前哨淋巴结活检[J]. 山东大学学报 (医学版), 2022, 60(8): 1-5. |
[5] | 孙丽娜,杜晓晓,张红娟,孟金来. 人类白细胞抗原G调控蜕膜自然杀伤细胞促进滋养细胞侵袭[J]. 山东大学学报 (医学版), 2022, 60(6): 41-45. |
[6] | 李琳琳,王凯. 基于生物信息学预测肝细胞癌预后基因[J]. 山东大学学报 (医学版), 2022, 60(5): 50-58. |
[7] | 赵婷婷,齐亚娜,张颖,袁冰,韩明勇. 小鼠乳腺癌诱导转移前肺组织微环境的改变[J]. 山东大学学报 (医学版), 2022, 60(4): 24-29. |
[8] | 陈兆波,方敏,薛浩然,刘春艳. 去泛素化酶USP35促进非小细胞肺癌细胞迁移和侵袭[J]. 山东大学学报 (医学版), 2022, 60(4): 30-37. |
[9] | 钟黎黎,盛莹,郭江虹,阳双健,何宜静. LncRNA-UCA1通过靶向调控miR-182-5p对滋养细胞侵袭与转移的影响[J]. 山东大学学报 (医学版), 2022, 60(3): 76-82. |
[10] | 修德健,高正文,宋婷婷,崔楠,崔静,孙健平. 生物信息学方法分析与宫颈癌有关联的基因[J]. 山东大学学报 (医学版), 2022, 60(10): 99-109. |
[11] | 冯鑫鑫,韩波,张丽,马孟洁,陈思宇. 长链非编码RNA NONHSAT247814.1在18例儿童心肌炎中的表达及体外细胞实验观察[J]. 山东大学学报 (医学版), 2022, 60(10): 27-32. |
[12] | 封海岗,刘国文,曹洪. 干扰MAD2L1基因表达对乳腺癌细胞凋亡的影响及机制[J]. 山东大学学报 (医学版), 2022, 60(10): 9-16. |
[13] | 初竹秀,赵文静,李小燕,孔晓丽,马婷婷,江立玉,杨其峰. 218例女性乳腺癌患者行新辅助化疗及伴随分子标志物改变的临床价值[J]. 山东大学学报 (医学版), 2021, 59(9): 130-139. |
[14] | 王喆,刘玉洁,毛倩,管佩霞,包绮晗,李承圣,乔晓伟,潘庆忠,王素珍. 基于逆概率加权法的早期三阴性乳腺癌不同治疗方案的疗效评价[J]. 山东大学学报 (医学版), 2021, 59(8): 113-118. |
[15] | 李皖皖,周文凯,董书晴,贺士卿,刘钊,张家新,刘斌. 利用数据库信息构建乳腺癌免疫关联lncRNAs风险评估模型[J]. 山东大学学报 (医学版), 2021, 59(7): 74-84. |
|